Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew D Goodman

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Journal of Behavioral Medicine|February 25, 2016
Erratum to: The interrelations between spiritual well-being, pain interference and depressive symptoms in patients with multiple sclerosisSheri A Nsamenang, Jameson K Hirsch, Raluca Topciu, et al.
Journal of the Neurological Sciences|March 3, 2007
Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trialSteven R Schwid, Andrew D Goodman, Amy Weinstein, et al.
Journal of Behavioral Medicine|January 24, 2016
The interrelations between spiritual well-being, pain interference and depressive symptoms in patients with multiple sclerosisSheri A Nsamenang, Jameson K Hirsch, Raluca Topciu, et al.
The Journal of Infectious Diseases|April 30, 2003
Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesionsAndrew D Goodman, David J Mock, James M Powers, et al.
International Journal of MS Care|October 23, 2014
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosisAndrew D Goodman, Theodore R Brown, Randall T Schapiro, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 30, 2003
Cognitive fatigue during a test requiring sustained attention: a pilot studySteven R Schwid, Carolyn M Tyler, Eileen A Scheid, et al.
Journal of Neurology|November 23, 2023
Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS ConsortiumDejan Jakimovski, Katelyn S Kavak, Patricia K Coyle, et al.
BMC Neurology|April 9, 2014
The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosisEdward Fox, Barbara Green, Clyde Markowitz, et al.
JAMA Neurology|September 3, 2014
The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosisJeffrey A Cohen, Arun V Krishnan, Andrew D Goodman, et al.
Muscle & Nerve|September 1, 2010
Broadening the spectrum of controls for skin biopsy in painful neuropathiesDavid N Herrmann, Alec B O'Connor, Steven R Schwid, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Journal of Behavioral Medicine|February 25, 2016
Erratum to: The interrelations between spiritual well-being, pain interference and depressive symptoms in patients with multiple sclerosisSheri A Nsamenang, Jameson K Hirsch, Raluca Topciu, et al.
Journal of the Neurological Sciences|March 3, 2007
Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trialSteven R Schwid, Andrew D Goodman, Amy Weinstein, et al.
Journal of Behavioral Medicine|January 24, 2016
The interrelations between spiritual well-being, pain interference and depressive symptoms in patients with multiple sclerosisSheri A Nsamenang, Jameson K Hirsch, Raluca Topciu, et al.
The Journal of Infectious Diseases|April 30, 2003
Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesionsAndrew D Goodman, David J Mock, James M Powers, et al.
International Journal of MS Care|October 23, 2014
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosisAndrew D Goodman, Theodore R Brown, Randall T Schapiro, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 30, 2003
Cognitive fatigue during a test requiring sustained attention: a pilot studySteven R Schwid, Carolyn M Tyler, Eileen A Scheid, et al.
Journal of Neurology|November 23, 2023
Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS ConsortiumDejan Jakimovski, Katelyn S Kavak, Patricia K Coyle, et al.
BMC Neurology|April 9, 2014
The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosisEdward Fox, Barbara Green, Clyde Markowitz, et al.
JAMA Neurology|September 3, 2014
The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosisJeffrey A Cohen, Arun V Krishnan, Andrew D Goodman, et al.
Muscle & Nerve|September 1, 2010
Broadening the spectrum of controls for skin biopsy in painful neuropathiesDavid N Herrmann, Alec B O'Connor, Steven R Schwid, et al.
Pageof 5